APOE and risk of cognitive impairment in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 100, Issue 5, 1999, Pages 290-295

  Oliveri, R L ^a,b   Cittadella, R ^b   Sibilia, G ^a   Manna, I ^b   Valentino, P ^a   Gambardella, A ^a,b   Aguglia, U ^a   Zappia, M ^a   Romeo, N ^b   Andreoli, V ^b   Bono, F ^a   Caracciolo, M ^b   Quattrone, Aldo ^a,b,c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b CNR   (Italy)

^c Policlinico Mater Domini   (Italy)

Author keywords

APOE gene; Cognitive impairment; Genetic polymorphism; Multiple sclerosis

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST;

EID: 0032859555     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1999.tb00398.x     Document Type: Article

References (32)

1. RAO SM. Neuropsychology of multiple sclerosis: a critical review. J Clin Exp Neuropsychol 1986;8:503-42.
2. RAO MS, LEO GJ, BERNARDIN L, UNVERZAGT F. Cognitive dysfunction in multiple sclerosis. I Frequency, patterns, and prediction. Neurology 1991;41:685-91.
3. ROVARIS M, FILIPPI M, FALAUTANO M et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 1998;50:1601-8.
4. JENNEKENS-SHINKEL A, LA BOYRIE PM, LANSER JBK, VAN DER VELDE EA. Cognition in patients with multiple sclerosis after four years. J Neurol Sci 1990;99:229-47.
5. MARIANI C, FARINA E, CAPPA SF et al. Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging. J Neurol 1991;238:395-400.
6. AMATO MP, PONZIANI G, PRACUCCI G, BRACCO L, SIRACUSA G, AMADUCCI L. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 1995;52:168-72.
7. KUJALA P, PORTIN R, RUUTIAINEN J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 1997;120:289-97.
8. MAYEUX R, SAUNDERS AM, SHEA S et al. Utility of apolipo-protein e genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998;338:506-11.
9. 4 allele frequency in age-related memory decline. Ann Neurol 1996;39:548-51.
10. BULLIDO MJ, ARTIGA MJ, RECUERO M et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 1998;18:69-71.
11. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guideline for research protocol. Ann Neurol 1983:13:227-31.
12. LUBLIN FD, REINGOLD SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
13. FOONG J, ROZEWICZ L, QUAGHEBEUR G, THOMPSON AJ, MILLER DH, RON MA. Neuropsychological deficits in multiple sclerosis after acute relapse. J Neurol Neurosurg Psychiatry 1998;64:529-32.
14. OLIVERI RL, SIBILIA G, VALENTINO P, RUSSO C, ROMEO N, QUATTRONE, A. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 1998:97:366-99.
15. KURIZKE JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
16. FOLSTEIN MF, FOLSTEIN SE, McHUGH PR. "Mini Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
17. REY A. L'examen clinique en psychologie. Paris: Presses Universitaire de France, 1964.
18. BORKOWSKY JG, BENTON AL, SPEAN D. Word fluency and brain damage. Neuropsychologia 1967;5:135-40.
19. CORSI P. Interhemispheric differences in the localization of psychological processes in man. Thesis. Montreal: University of Montreal, 1972.
20. RAVEN JC. Progressive Matrices (1947) Sets A, AbB: Board and Book forms. London: HK Lewis, 1947.
21. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;5:56-62.
22. CARLESIMO GA, CALTAGIRONE C, GAINOTTI G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 1996:36:378-84.
23. SPINNLER H, TOGNONI G. Standardizzazione e taratura italiana dei test neuropsicologici. It J Neurol Sci 1987; 6:8-250.
24. CRUM MR, ANTHONY JC, BASSETT SS, FOLSTEIN MF. Population-based norms for the mini-mental state examination by age and educational level. JAMA 1993:269: 2386-91.
25. RUBINSZTEIN DC, HANLON CS, IRVING RM et al. Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Mol Cell Probes 1994;8:519-25.
26. GERVAIS A, GAILLARD O, PLASSART E, REBOUL J, FONTAINE B, SCHULLER E. Apolipoprotein E polymorphism in multiple sclerosis. Ann Clin Biochem 1998;35:135-6.
27. FEINSTEIN A, RON M, THOMPSON A. A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis. Brain 1993;116:569-602.
28. COMI G, FILIPPI M, MARTINELLI V et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 1995;132:222-7.
29. BEATTY WW, GOODKIN DE, HERTSGAARD D et al. Clinical and demographic predictors of cognitive performance in multiple sclerosis: do diagnostic type, disease duration, and disability matter? Arch Neurol 1990;47:305-8.
30. BONDI MW, KASZNIAK AW, Implicit and explicit memory in Alzheimer's disease and Parkinson's disease. J Clin Exp Neuropsychol 1991;13:339-58.
31. SCARRABELLOTTI M, CARROLL M. Awareness of remembering achieved through automatic and conscious processes in multiple sclerosis. Brain Cogn 1998;38:183-201.
32. MIYATA M, SMITH JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and b-amyloid peptides. Nat Genet 1996;14:55-61.